文献速递甲状腺疾病

亚急性甲状腺炎是SARS-CoV-2感染被低估的表现吗?来自病例系列的启示

Is Subacute Thyroiditis an Underestimated Manifestation of SARS-CoV-2 Infection? Insights From a Case Series.
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

该病例系列描述了4例与SARS-CoV-2感染相关的亚急性甲状腺炎(SAT)女性患者(年龄29-46岁),SAT在COVID-19缓解后16至36天出现。主要症状为颈部疼痛放射至下颌及心悸,伴发热和乏力。作者认为SAT可能是COVID-19被低估的表现,临床医生应警惕SARS-CoV-2感染期间及之后可能发生SAT。

要点

  • 4例女性在COVID-19缓解后16-36天出现SAT,年龄29-46岁。
  • 主要症状为颈部疼痛放射至下颌、心悸,伴发热和乏力;1例因心房颤动住院。
  • 3例接受泼尼松、1例接受布洛芬治疗后症状数日内消失;6周后2例甲状腺功能正常、2例诊断为亚临床甲状腺功能减退。

核心结论

  • SAT可能是COVID-19被低估的表现。
  • 临床医生应牢记SARS-CoV-2感染期间及之后可能发生SAT。

研究设计与样本

  • 病例系列,描述4例与SARS-CoV-2感染相关的SAT患者的临床、生化和影像学特征。

主要发现

  • 所有患者均为女性,年龄29-46岁。
  • SAT在COVID-19缓解后16至36天出现。
  • 颈部疼痛放射至下颌和心悸为主要就诊症状,并伴有发热和乏力。
  • 1例患者因心房颤动住院。
  • 3例可获得的甲状腺功能检查提示破坏性甲状腺炎,炎症标志物升高。

临床怎么用

  • 作者认为SAT可能是COVID-19被低估的表现。
  • 作者建议临床医生应牢记SARS-CoV-2感染期间及之后可能发生SAT。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected more than 18 million people worldwide and the pandemic is still spreading. After the first case we reported, we observed 4 additional cases of subacute thyroiditis (SAT) related to SARS-CoV-2 infection. OBJECTIVES: The objective of this work is to describe additional cases of SAT associated with SARS-CoV-2 infection to alert physicians that SAT may be a manifestation of SARS-CoV-2 infection. METHODS: We describe clinical, biochemical, and imaging features of 4 patients with SAT related to SARS-CoV-2 infection. RESULTS: All patients were female (age, 29-46 years). SAT developed 16 to 36 days after the resolution of coronavirus disease 2019 (COVID-19). Neck pain radiated to the jaw and palpitations were the main presenting symptoms and were associated with fever and asthenia. One patient was hospitalized because of atrial fibrillation. Thyroid function tests (available for 3 individuals) were suggestive of destructive thyroiditis, and inflammatory markers were high. At neck ultrasound the thyroid was enlarged, with diffuse and bilateral hypoechoic areas and (in 3 patients) absent vascularization at color Doppler. Symptoms disappeared a few days after commencement of treatment (prednisone in 3 patients and ibuprofen in 1). Six weeks after the onset of SAT, all patients were asymptomatic and inflammatory markers had returned to normal range. Two patients were euthyroid, whereas 2 were diagnosed with subclinical hypothyroidism. CONCLUSIONS: SAT may be an underestimated manifestation of COVID-19. Clinicians should keep in mind the possible occurrence of SAT during and after SARS-CoV-2 infection.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Brancatella A, Ricci D, Cappellani D, et al. Is Subacute Thyroiditis an Underestimated Manifestation of SARS-CoV-2 Infection? Insights From a Case Series. J Clin Endocrinol Metab. 2020. PMID: 32780854. doi:10.1210/clinem/dgaa537

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。